LIK 066

Drug Profile

LIK 066

Alternative Names: LIK-066

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihyperglycaemics
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 01 Apr 2016 Novartis completes a phase II trial for Type 2 diabetes mellitus in USA (NCT02470403)
  • 10 Jun 2015 Novartis initiates enrolment in a phase II trial for Type 2 diabetes mellitus in USA (NCT02470403)
  • 02 Apr 2014 Novartis withdraws a phase II trial for Type-2 diabetes mellitus prior to enrolment in USA, Poland, Argentina, Hungary, Puerto Rico and South Africa (NCT01824264)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top